Shanghai Junshi Biosciences' Subsidiary Gets GMP Compliance Certificate From Irish Regulator

Shanghai Junshi Biosciences' (HKG:1877) subsidiary Suzhou Union Biopharm, has received a critical Good Manufacturing Practice (GMP) compliance certificate for a manufacturer from the Irish Health

MT NewswiresJul 11 03:44 ET

HK stocks saw unusual movement as the biomedical sector rallied, boosted by bullish policies for innovative drugs. There are still multiple catalysts for the sector in the second half of the year.

According to the Wise Money APP, biopharmaceutical stocks rebounded collectively. As of the press release, Remegen (09995) rose by 8.06%, to HKD 14.74; Kexing Biotech-B (06990) rose by 7.46%, to HKD 142.6; Genscript Biotech (01548) rose by 5.08% to HKD 9.52, and Junshi Bio (01877) rose by 4.17% to HKD 13. News-wise, on July 5th, the State Council's executive meeting reviewed and approved the "Implementation Plan for Supporting the Development of Innovative Drugs throughout the Entire Chain." Previously, the National Medical Insurance Bureau released the "First Launch Price of New Marketed Chemical Drugs".

Zhitong FinanceJul 10 22:23 ET

Express News | Shanghai Junshi Biosciences - Unit Received Certificate of Gmp Compliance of a Manufacturer

ReutersJul 10 09:11 ET

Junshi Bio (01877.HK): The production facilities for Toripalimab injection have passed the EU GMP certification for the first time among member states.

On July 10th, GeLongHui reported that Junshi Bio (01877.HK) recently announced that its wholly-owned subsidiary, Suzhou Zhonghe Biomedical Technology Co., Ltd., received the CERTIFICATE OF GMP COMPLIANCE OF based on relevant regulations issued by the European Medicines Agency (EMA) by the Ireland Health Products Regulatory Authority.

Gelonghui FinanceJul 10 06:17 ET

Junshi Bio (688180.SH): Subsidiary passes EU GMP certification.

Junshi Bio (688180.SH) announced that its wholly-owned subsidiary, Suzhou Zhonghe Biomedical Technology Co., Ltd., ...

Zhitong FinanceJul 10 05:14 ET

Shanghai Junshi Biosciences Malignant Tumor Drugs Gets NMPA's Nod

Shanghai Junshi Biosciences Co (HKG:1877, SHA:688180) said China's National Medical Products Administration (NMPA) approved the new drug application for JS125, a drug meant to treat malignant tumors,

MT NewswiresJul 10 03:36 ET